EC Number   |
Application |
Reference |
|---|
   3.4.22.B70 | diagnostics |
enzyme SENP1 is an important cancer metastasis-related molecule and may be a prognostic marker and a therapeutic target for metastasis in prostate cancer patients |
731513 |
| 3.4.22.B70 | diagnostics |
SENP1 may serve as a potential diagnostic and therapeutic target of pancreatic ductal adenocarcinoma |
732963 |
| 3.4.22.B70 | drug development |
SENP1 is a potential therapeutic target for the treatment of prostate cancers |
717356 |
| 3.4.22.B70 | drug development |
SENP1 is an essential gene and is a potential target for developing therapeutic agents for cancer |
732570 |
| 3.4.22.B70 | drug development |
the enzyme is a drug target for development of small molecule drugs against prostate cancer |
731438 |
| 3.4.22.B70 | medicine |
diagnostic value of measuring the urinary content of SENP1 mRNAs for detection of tumor recurrence |
714614 |
| 3.4.22.B70 | medicine |
SENP1 expression has strong prognostic impact in a molecularly defined subset of cancers. In the subgroup of ERG positive, PTEN undeleted cancers, the prognostic role of SENP1 expression is independent of the preoperative PSA level, tumor stage, Gleason grade, and the status of the resection |
753090 |
| 3.4.22.B70 | medicine |
SENP1 is overexpressed in most of colon cancer tissues. SENP1 regulates the in vitro and in vivo growth of colon cancer cells with the upregulated expression of CDK inhibitors |
714646 |
| 3.4.22.B70 | medicine |
SENP1 overexpression induces transformation of the normal prostate gland and gradually facilitates the onset of high-grade prostatic intraepithelial neoplasiade. SUMOylation plays a critical role in prostate pathogenesis through induction of HIF1alpha-dependent angiogenesis and enhanced cell proliferation |
715527 |
| 3.4.22.B70 | medicine |
SENP1, can transform normal prostate epithelia to a dysplasic state and directly modulate several oncogenic pathways in prostate cells, including AR, c-Jun, and Cyclin D1 |
715108 |
